Key result
Intracellular angiotensin II signaling sustains mitochondrial fission in HF despite RAAS blockade, presenting a new target.
Why the study?
Despite RAAS inhibition improving survival in heart failure, mitochondrial dynamic dysfunction persists, indicating intracellular signalling mechanisms sustain pathological remodelling.
Targeting mitochondrial dynamics may serve as a complementary therapeutic strategy to overcome limitations of current RAAS inhibition in heart failure.
Answers are grounded in this paper and cite their sources.
Intracellular Ang II effects on mitochondrial fission may persist despite RAAS blockade; leaves open complementary mitochondrial-targeted strategies in HF.
Heart failure (HF) remains a leading cause of morbidity and mortality worldwide despite significant advances in neurohumoral therapies targeting the renin-angiotensin-aldosterone (RAAS). Although RAAS inhibition improves survival and limits adverse cardiac remodelling in failing hearts, mitochondrial dynamic dysfunction persists in a larger proportion of treated patients, indicating an intracellular signalling mechanism that sustains the pathological remodelling in these patients. Emerging evidence shows a shift toward a fission-dominant mitochondrial phenotype, acting as a critical feature of a failing heart. Angiotensin II (Ang II), beyond its classical endocrine actions, activates a network of calcium- and redox-dependent intracellular signalling pathways that converge on the mitochondrial fission machinery. Many of these components are incompletely inhibited by the conventional RAAS blockade, providing a mechanistic basis for RAAS escape and persistent mitochondrial dysfunction. This review highlights the mechanism underlying the temporal stabilization of fission-dominant mitochondrial phenotype, and discusses the opportunity to target mitochondrial dynamics as a complementary therapeutic strategy. Reframing angiotensin signalling through the lens of mitochondrial dysregulated dynamics may help overcome the limitations of current heart failure therapies.
No takes yet. Share an insight, caveat, or question.
Panchbhai et al. (2026) conducted a review in Heart failure. Intracellular angiotensin signalling and mitochondrial dynamics was evaluated. Intracellular angiotensin II signalling sustains pathological mitochondrial fission in heart failure despite conventional RAAS blockade, presenting a potential complementary therapeutic target.
Synapse has enriched 10 related papers. Consider them for comparative context: